Exenatide enhances INS-1 rat pancreatic beta-cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein

摘要

Type 2 diabetes mellitus (T2DM) is a complex and heterogeneous disorder affecting >220 million individuals worldwide; this is projected to reach 366 million by 2030. Exenatide, a long-acting glucagon-like peptide 1 receptor agonist, exhibits potential in the treatment of T2MD due to its ability to increase beta-cell mass. However, the molecular mechanism by which exenatide increases beta-cell mass is yet to be elucidated. Exenatide function was explored in the INS-1 rat pancreatic beta-cell line. Exenatide was found to increase adiponectin protein levels by 20% (P<0.05 versus the control group) and reduce the level of C-reactive protein (CRP) by 50% (P<0.01 versus the control group) in INS-1 cells, resulting in an increase in the INS-1 rat pancreatic beta-cell mass by 20% (P<0.01 versus the control group). These findings suggest that exenatide may ameliorate T2DM by increasing adiponectin protein levels and reducing the level of CRP.